Basanite, INC

Market Movers (8-K)

OTC.Pink
Basanite, Inc. terminated its independent registered public accounting firm, Hudgens CPA, PLLC, after discovering the firm withdrew from the PCAOB and ceased operations without notification.
Worse than expected
OTC.Pink
Ronald LoRicco, Sr. has resigned as Acting Interim Chief Financial Officer of Basanite, Inc., while continuing his roles as Acting Interim CEO and Chairman of the Board.
OTC.Pink
Basanite, Inc. announced the retirement of Frederick Tingberg from his roles as Chief Technology Officer and Board Director, effective August 15, 2025.
Worse than expected
OTC.Pink
Basanite, Inc. announced the resignation of four directors, including its Acting Interim Chief Financial Officer, raising significant corporate governance concerns.
Worse than expected
OTC.Pink
Basanite, Inc. announces the reappointment of Ronald LoRicco, Sr. as Acting Interim Chief Executive Officer, effective immediately, following Mike Nelson's departure.
OTC.Pink
Basanite, Inc. appoints Michael Dennis Nelson as CEO effective March 18, 2025, granting him a salary and stock options contingent on future financing milestones.
Capital raise

Quarterly Earnings (10-Q)

OTC.Pink
Basanite, Inc. reports significant revenue decline, negative gross profit, zero cash, and substantial doubt about its ability to continue as a going concern in its latest 10-Q filing.
Worse than expected
Capital raise
Delay expected
OTC.Pink
Basanite, Inc. reports significant revenue decline, increased losses, and substantial doubt about its ability to continue as a going concern, amidst paused manufacturing and mounting debt.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Basanite Inc.'s Q1 2025 results reveal a decrease in revenue and continued net losses, highlighting the company's struggle with manufacturing constraints and limited working capital.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Basanite Inc.'s Q3 2024 results reveal ongoing financial difficulties, including net losses and a working capital deficiency, while the company focuses on restructuring and securing additional funding.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Basanite Inc.'s Q2 2024 results reveal ongoing financial struggles with reduced revenue and operating losses, alongside efforts to address manufacturing and compliance issues.
Worse than expected
Capital raise
OTC.Pink
Basanite Inc. reports a net loss of $287,958 for the first quarter of 2024, with revenue decreasing to $59,449, highlighting ongoing financial and operational challenges.
Worse than expected
Delay expected
Capital raise

Annual Reports (10-K)

OTC.Pink
Basanite, Inc.'s 10-K filing reveals ongoing operating losses and substantial doubt about its ability to continue as a going concern, despite a slight increase in revenue.
Worse than expected
Capital raise
OTC.Pink
Basanite Inc.'s amended 10-K filing reveals ongoing financial challenges, including material weaknesses in internal controls and substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Basanite Inc.'s 10-K filing reveals significant operating losses, limited cash resources, and substantial doubt about the company's ability to continue as a going concern, despite efforts to expand manufacturing and sales.
Worse than expected
Delay expected
Capital raise